Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Derer, Anja ^a   Groetsch, Bettina ^a   Harre, Ulrike ^a   Böhm, Christina ^a   Towne, Jennifer ^b   Schett, Georg ^a   Frey, Silke ^a   Hueber, Axel J ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE ANTIBODY; INTERLEUKIN 36 RECEPTOR; INTERLEUKIN 36ALPHA; INTERLEUKIN RECEPTOR; M 616; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN-36 RECEPTOR, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE METABOLISM; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; HUMAN; HUMAN CELL; KNEE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; ARTHRITIS; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ARTHRITIS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1; KNEE JOINT; MALE; MICE; MICE, TRANSGENIC; OSTEOCLASTS; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION;

EID: 84905841649     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101954     Document Type: Article

References (19)

1. Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, et al. (2000) Four new members expand the interleukin-1 superfamily. J Biol Chem 275: 1169-1175. (Pubitemid 30051168)
2. Towne J, Sims J (2012) IL-36 in psoriasis. Curr Opin Pharmacol.
3. Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, et al. (2007) Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 204: 2603-2614. (Pubitemid 350044786)
4. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, et al. (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365: 620-628.
5. Blumberg H, Dinh H, Dean C, Jr., Trueblood ES, Bailey K, et al. (2010) IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol 185: 4354-4362.
6. Carrier Y, Ma HL, Ramon HE, Napierata L, Small C, et al. (2011) Interregulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 131: 2428-2437.
7. Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, et al. (2011) IL-36R ligands are potent regulators of dendritic and T cells. Blood 118: 5813-5823.
8. Magne D, Palmer G, Barton JL, Mezin F, Talabot-Ayer D, et al. (2006) The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 8: R80.
9. Frey S, Derer A, Messbacher ME, Baeten DL, Bugatti S, et al. (2013) The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis.
10. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, et al. (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10: 4025-4031. (Pubitemid 21905432)
11. Gortz B, Hayer S, Redlich K, Zwerina J, Tohidast-Akrad M, et al. (2004) Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation. J Bone Miner Res 19: 990-998. (Pubitemid 41103456)
12. Ochi S, Shinohara M, Sato K, Gober HJ, Koga T, et al. (2007) Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc Natl Acad Sci U S A 104: 11394-11399. (Pubitemid 47175151)
13. Redlich K, Gortz B, Hayer S, Zwerina J, Kollias G, et al. (2004) Overexpression of tumor necrosis factor causes bilateral sacroiliitis. Arthritis Rheum 50: 1001-1005. (Pubitemid 38326202)
14. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, et al. (2004) Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50: 277-290. (Pubitemid 38084313)
15. Zwerina K, Koenders M, Hueber A, Marijnissen RJ, Baum W, et al. (2012) Anti IL-17A therapy inhibits bone loss in TNF-alpha-mediated murine arthritis by modulation of the T-cell balance. Eur J Immunol 42: 413-423.
16. Axmann R, Bohm C, Kronke G, Zwerina J, Smolen J, et al. (2009) Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 60: 2747-2756.
17. Axmann R, Herman S, Zaiss M, Franz S, Polzer K, et al. (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67: 1603-1609.
18. Herrak P, Gortz B, Hayer S, Redlich K, Reiter E, et al. (2004) Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 50: 2327-2337. (Pubitemid 38924413)
19. Lamacchia C, Palmer G, Rodriguez E, Martin P, Vigne S, et al. (2013) The severity of experimental arthritis is independent of IL-36 receptor signaling. Arthritis Res Ther 15: R38.